PecFent

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

fentanil

Available from:

Kyowa Kirin Holdings B.V.

ATC code:

N02AB03

INN (International Name):

fentanyl

Therapeutic group:

analgetici

Therapeutic area:

Pain; Cancer

Therapeutic indications:

PecFent je indiciran za liječenje probojne boli kod odraslih koji već primaju opioidnu terapiju za održavanje kronične boli u raku. Probijanje boli je prolazno pogoršanje boli koja se javlja na pozadini drugačije kontrolirane upornosti boli. Pacijentima prima održavanje pta to su oni koji ne uzimaju manje od 60 mg oralnog morfina u dan, kao i najmanje 25 mg трансдермального fentanila na sat, ne manje od 30 mg oksikondon svakodnevno barem 8 mg dnevno usmeni гидроморфон ili ekvivalent analgetik u dozi od druge опиоидный za tjedan dana ili više.

Product summary:

Revision: 23

Authorization status:

odobren

Authorization date:

2010-08-31

Patient Information leaflet

                                39
B. UPUTA O LIJEKU
40
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
PECFENT 100 MIKROGRAMA/POTISAK SPREJ ZA NOS, OTOPINA
PECFENT 400 MIKROGRAMA/POTISAK SPREJ ZA NOS, OTOPINA
fentanil
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
•
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
•
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
•
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
•
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je PecFent i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati PecFent
3.
Kako primjenjivati PecFent
4.
Moguće nuspojave
5.
Kako čuvati PecFent
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE PECFENT I ZA ŠTO SE KORISTI
ŠTO JE PECFENT
PecFent sadrži fentanil, koji je snažan lijek za ublažavanje bolova
poznat kao opioidni analgetik.
ZA ŠTO SE PECFENT KORISTI
PecFent koriste odrasli bolesnici s rakom za vrstu boli koja se naziva
'probijajuća bol'.
•
Probijajuća bol nastupa naglo.
•
Bol se pojavi iako ste uzeli svoj uobičajeni opioidni analgetik (kao
što su morfij, fentanil,
oksikodon ili hidromorfon) protiv stalno prisutnih bolova.
PecFent smiju upotrebljavati samo odrasli bolesnici koji već uzimaju
druge opioidne lijekove protiv
stalnih bolova povezanih s rakom.
NA KOJI NAČIN PECFENT DJELUJE
PecFent je sprej za nos, otopina.
•
Kada raspršite PecFent u nos vrlo male kapljice spreja oblikuju tanki
gel.
•
Fentanil se brzo apsorbira kroz unutrašnju sluznicu nosa i zatim u
optok krvi.
•
To znači da lijek brzo ulazi u tijelo kako bi ublažio probijajuću
bol.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE PRIMJENJIVATI PECFENT
NEMOJTE PRIMJENJIVATI PECFENT:
•
ako ste alergični na fentani
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
PecFent 100 mikrograma/potisak sprej za nos, otopina
PecFent 400 mikrograma/potisak sprej za nos, otopina
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
PecFent 100 mikrograma/potisak sprej za nos, otopina
Jedan ml otopine sadrži 1000 mikrograma fentanila (u obliku
fentanilcitrata).
Jedan potisak (100 mikrolitara) sadrži 100 mikrograma fentanila (u
obliku fentanilcitrata).
Bočice sadrže:
0,95 ml (950 mikrograma fentanila) - bočica s 2 potiska
ili
1,55 ml (1550 mikrograma fentanila) - bočica s 8 potisaka
PecFent 400 mikrograma/potisak sprej za nos, otopina
Jedan ml otopine sadrži 4000 mikrograma fentanila (u obliku
fentanilcitrata).
Jedan potisak (100 mikrolitara) sadrži 400 mikrograma fentanila (u
obliku fentanilcitrata).
Jedna bočica sadrži 1,55 ml (6200 mikrograma fentanila).
Pomoćne tvari s poznatim učinkom:
Jedan potisak sadrži 0,02 mg propilparahidroksibenzoata (E216).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Sprej za nos, otopina (sprej za nos)
Bistra do gotovo bistra bezbojna vodena otopina.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
PecFent je indiciran za zbrinjavanje probijajuće boli u odraslih koji
već primaju opioidnu terapiju
održavanja protiv kronične boli uzrokovane rakom. Probijajuća bol
je prolazna egzacerbacija boli koja
se dodatno javlja uz već kontroliranu upornu dugotrajnu bol.
Bolesnici koji primaju opioidnu terapiju održavanja su oni koji
uzimaju najmanje 60 mg peroralnog
morfina na dan, najmanje 25 mikrograma transdermalnog fentanila na
sat, najmanje 30 mg oksikodona
na dan, najmanje 8 mg peroralnog hidromorfona na dan ili
ekvianalgetsku dozu nekog drugog opioida
tjedan dana ili dulje.
4.2
DOZIRANJE I NAČIN PRIMJENE
Liječenje mora započeti i nadzirati liječnik s iskustvom u primjeni
opioidne terapije u bolesnika s
rakom. Liječnici moraju voditi računa o mogućnosti zlouporabe
fentanila.
3
Doziranje
PecFent se mora titrirati na “djelotvornu” dozu, koja u dvije
uzastopn
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-04-2024
Public Assessment Report Public Assessment Report Bulgarian 03-08-2018
Patient Information leaflet Patient Information leaflet Spanish 04-04-2024
Public Assessment Report Public Assessment Report Spanish 03-08-2018
Patient Information leaflet Patient Information leaflet Czech 04-04-2024
Public Assessment Report Public Assessment Report Czech 03-08-2018
Patient Information leaflet Patient Information leaflet Danish 04-04-2024
Public Assessment Report Public Assessment Report Danish 03-08-2018
Patient Information leaflet Patient Information leaflet German 04-04-2024
Public Assessment Report Public Assessment Report German 03-08-2018
Patient Information leaflet Patient Information leaflet Estonian 04-04-2024
Public Assessment Report Public Assessment Report Estonian 03-08-2018
Patient Information leaflet Patient Information leaflet Greek 04-04-2024
Public Assessment Report Public Assessment Report Greek 03-08-2018
Patient Information leaflet Patient Information leaflet English 04-04-2024
Public Assessment Report Public Assessment Report English 03-08-2018
Patient Information leaflet Patient Information leaflet French 04-04-2024
Public Assessment Report Public Assessment Report French 03-08-2018
Patient Information leaflet Patient Information leaflet Italian 04-04-2024
Public Assessment Report Public Assessment Report Italian 03-08-2018
Patient Information leaflet Patient Information leaflet Latvian 04-04-2024
Public Assessment Report Public Assessment Report Latvian 03-08-2018
Patient Information leaflet Patient Information leaflet Lithuanian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-04-2024
Public Assessment Report Public Assessment Report Lithuanian 03-08-2018
Patient Information leaflet Patient Information leaflet Hungarian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 04-04-2024
Public Assessment Report Public Assessment Report Hungarian 03-08-2018
Patient Information leaflet Patient Information leaflet Maltese 04-04-2024
Public Assessment Report Public Assessment Report Maltese 03-08-2018
Patient Information leaflet Patient Information leaflet Dutch 04-04-2024
Public Assessment Report Public Assessment Report Dutch 03-08-2018
Patient Information leaflet Patient Information leaflet Polish 04-04-2024
Public Assessment Report Public Assessment Report Polish 03-08-2018
Patient Information leaflet Patient Information leaflet Portuguese 04-04-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 04-04-2024
Public Assessment Report Public Assessment Report Portuguese 03-08-2018
Patient Information leaflet Patient Information leaflet Romanian 04-04-2024
Public Assessment Report Public Assessment Report Romanian 03-08-2018
Patient Information leaflet Patient Information leaflet Slovak 04-04-2024
Public Assessment Report Public Assessment Report Slovak 03-08-2018
Patient Information leaflet Patient Information leaflet Slovenian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 04-04-2024
Public Assessment Report Public Assessment Report Slovenian 03-08-2018
Patient Information leaflet Patient Information leaflet Finnish 04-04-2024
Public Assessment Report Public Assessment Report Finnish 03-08-2018
Patient Information leaflet Patient Information leaflet Swedish 04-04-2024
Public Assessment Report Public Assessment Report Swedish 03-08-2018
Patient Information leaflet Patient Information leaflet Norwegian 04-04-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 04-04-2024
Patient Information leaflet Patient Information leaflet Icelandic 04-04-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 04-04-2024

Search alerts related to this product

View documents history